PFS and OS by BRCA1 Genotypes in Treatment Groups
BRCA1
mut
BRCA1
wt
BRCA1-mutated
patients
treated with T+PLD
showed
longer PFS and OS
compared to PLD.
XPG-mutated patients
treated with T+PLD had
shorter PFS compared to
XPG-wildtype.
BRCA1
mut
may predict improved outcome to T+PLD
treatment and XPG may be a biomarker
of poor outcome in ROC.
Monk et al. Gynecologic Oncology 133 (2014) Abs 99
Analysis of OV-301 according to BRCA status
